MeMed Diagnostics
Diagnostic Tools for Infectious Diseases
Company Overview
Snapshot
Founded in June 2009 by Kfir Oved and Eran Eden, MeMed Diagnostics operates with 51–200 employees. The company has raised over $223.43 million across 11 funding rounds from 11 investors. In March 2026, Health Canada approved MeMed BV® on MeMed Key®.
Business overview
MeMed Diagnostics develops and validates immune-based protein signatures to distinguish between bacterial and viral infections. Its core products include MeMed BV, an immune-based protein signature, and MeMed Key, a platform designed for rapid measurement of multiple proteins and signatures at the point of care. The company serves the healthcare industry, operating within the digital health and medical technologies sector, with a focus on diagnostics, immunology, and personalized medicine.
Strategic signal
In March 2026, MeMed Diagnostics expanded its global footprint with Health Canada's approval of MeMed BV® on MeMed Key®. This regulatory clearance is a significant validation of the company's diagnostic technology and signals a strategic move into new markets, demonstrating its commitment to broader adoption of its infection differentiation solutions.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent regulatory approval for MeMed Diagnostics?
- In March 2026, Health Canada approved MeMed BV® on MeMed Key®, expanding MeMed Diagnostics' global presence.
- What was the total capital raised by MeMed Diagnostics?
- MeMed Diagnostics has raised over $223.43 million across 11 funding rounds.
- When did MeMed Diagnostics receive FDA clearance for its infection test?
- In September 2021, MeMed Diagnostics received 510(k) clearance from the FDA for MeMed BV for adults and children.
- Which healthcare service integrated MeMed BV® into routine care?
- In June 2022, Maccabi Healthcare Services became the first HMO globally to include the MeMed BV® test as part of routine care.
- What was a key partnership for MeMed Diagnostics in 2020?
- In September 2020, MeMed Diagnostics partnered with DiaSorin to develop and commercialize novel host immune response-based diagnostic solutions.